PDL1-MC2-TCR-T

PDL1-MC2-TCR-T is an investigational, engineered T cell therapy designed for cancer treatment. It consists of autologous human T cells that are genetically modified to express a recombinant T cell receptor (TCR) specific for the cancer-testis antigen MAGE-C2 (also known as MC2), and to co-express programmed death-ligand 1 (PD-L1). Additionally, these T cells have their endogenous PD-1 gene knocked out. The dual engineering strategy allows the modified T cells to target and kill MAGE-C2-expressing tumor cells while simultaneously activating PD-1 signaling in tumor cells (to suppress their proliferation) and preventing self-inhibition by eliminating PD-1 expression in the therapeutic T cells themselves. This approach aims to enhance cytotoxic efficacy against tumors by combining targeted immunotherapy with checkpoint pathway modulation[1]. The therapy is being developed primarily for solid tumors expressing MAGE-C2, such as melanoma and head and neck squamous cell carcinoma[7].